The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.
Through its membership of national associations and companies, EUCOPE represents more than 900 research-based organisations.
Many of EUCOPE’s member companies develop high-end innovative solutions, including gene and cell therapies, bringing these transformative therapies ever closer to European patients.
BioMarin is a global biopharmaceutical company and world leader in developing and commercialising first- or best-in-class therapies for rare genetic diseases. BioMarin takes pride in going where the science leads it, pioneering breakthrough treatments for debilitating and life-threatening conditions where it can significantly improve upon the current standard of care. Over the last 20 years, BioMarin has developed therapies for conditions including phenylketonuria (PKU), mucopolysaccharidosis (MPS), achondroplasia, and neuronal ceroid lipofuscinosis type 2 (CLN2), a form of Batten disease. BioMarin is a leader in gene therapy and has a ground-breaking pipeline including novel treatments for severe haemophilia A and hereditary angioedema. In Europe, Middle East and Africa, BioMarin markets six therapies and employs 700+ people across more than 50 countries, coordinated from its regional HQ in Ireland.
Follow BioMarin on LinkedIn.
Bristol Myers Squibb is a global biopharmaceutical company whose mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience.
Follow Bristol Myers Squibb on Linkedin.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North, South and Central America, Europe, Africa, Asia and Australia.
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe. Kite’s singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite currently has two approved CAR T products.
Follow Gilead Sciences on LinkedIn.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, they use innovative science and digital technologies to create transformative treatments in areas of great medical need. In the quest to find new medicines, the company consistently ranks among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and is finding innovative ways to expand access to their latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world.
Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, Novartis Gene Therapies are working to turn promising gene therapies into proven treatments. Powered by an extensive manufacturing footprint, enabling it to bring gene therapy to patients around the world at quality and scale.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk markets its products in around 170 countries.
Our success will be defined by the solutions we bring and the health and well-being of the people and communities benefiting from them.
At Spark® Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases. Our focus includes ocular, systemic and neuroscience. At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease.
Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) and continues to advance its research in CF. Vertex has a broad and deep pipeline, including small molecule approaches, and cell and genetic therapies, for other serious diseases like sickle cell disease, beta thalassemia, type 1 diabetes, APOL1-mediated kidney disease and pain.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma.
Our parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 25,000 people, and delivers its lifesaving therapies to people in more than 100 countries.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.
PTC’s ability to innovate to identify new therapies and globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. Its mission is to provide access to best-in-class treatments for patients who have little to no treatment options.
The company’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. This allows PTC to maximize value for all stakeholders.
Santen is a global specialist in ophthalmology, committed to reducing the loss of social and economic opportunities for people around the world living with eye conditions by 2030. Santen has a 130-year history of providing patients with pioneering treatments for eye conditions and is a market leader in its home market of Japan and in China. It has a commercial presence in over 60 countries and a portfolio that includes over-the-counter, prescription medicines and medical devices, with the recent addition of cell & gene therapy.
Santen aims to build a sustainable platform in advanced therapies by innovating at a pace that benefits society and changes patient lives.
At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment.
Orchard was founded in 2015—but our roots run deeper, going back to some of the first research and clinical development involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.
Medac is a privately held, medium-sized global pharmaceutical and diagnostics company based in Germany. For more than 50 years we have been committed to high quality products, reliable supply and individual customer services. Today, over 2.000 medac employees worldwide are working together to supply more than 90 countries with our products.
Since our incorporation we have been specializing in the treatment of oncological, haematological, urological, and autoimmune diseases. Today, we are a leading specialist supplier in oncology and rheumatology.
We combine the innovative power of a researching pharmaceutical company with the efficiency of a generics manufacturer and offer both therapeutics and diagnostics.
Always putting the needs of patients and healthcare professionals first, we are committed to the refinement of established and the development of new products with added benefits for patients in specific niche indications with high therapeutic needs.
Miltenyi Biomedicine is a biopharmaceutical company Headquartered in Bergish Gladbach, Germany. Our mission is to bring accessible and innovative cancer treatments and regenerative therapies to patients.
Building on Miltenyi’s decades of experience, we are uniquely positioned to realize the great potential of the new cell and gene therapies and make them available to patients worldwide.
Our clinical research and development program is focused on difficult-to-treat cancers – specifically, finding treatments for hematological cancers using CAR technology.
We are currently developing several platforms, including Chimeric Antigen Receptor T (CAR T) and CAR Natural Killer (CAR NK) cells, for the treatment of adult patients with hematological malignancies. We are also working on regenerative therapies for the treatment of Alzheimer’s disease, Parkinson’s disease, and diabetes in the elderly.